β-lactam/β-lactamase inhibitor combinations: an update

Area of Science:

• Microbiology
• Medicinal Chemistry
• Pharmacology

Background:

• Beta-lactamase production is a primary mechanism of antibiotic resistance, compromising the efficacy of beta-lactam antibiotics.
• Existing beta-lactamase inhibitors, like clavulanic acid, sulbactam, and tazobactam, are effective against certain classes but not all.
• Emerging inhibitors such as avibactam and vaborbactam broaden the spectrum but do not cover all resistant enzymes.

Purpose of the Study:

• To review recent FDA-approved beta-lactam/beta-lactamase inhibitor combinations.
• To provide an update on novel beta-lactamase inhibitor research and development.
• To address the ongoing challenge of antibiotic resistance mediated by beta-lactamases.

Main Methods:

• Literature review of recent FDA approvals for beta-lactam/beta-lactamase inhibitor combinations.
• Survey of current research on novel beta-lactamase inhibitor discovery.
• Analysis of inhibitor efficacy against different classes of beta-lactamases.

Main Results:

• Several new beta-lactam/beta-lactamase inhibitor combinations have been approved.
• Newer inhibitors show activity against carbapenemases like KPC.
• Significant gaps remain in inhibitor coverage for class D and class B beta-lactamases.

Conclusions:

• Despite advances, a substantial need exists for inhibitors effective against a wider range of beta-lactamases.
• Continued research is crucial for developing next-generation inhibitors to combat multidrug-resistant bacteria.
• Novel therapeutic strategies are essential to preserve the utility of beta-lactam antibiotics.